Table 1.
Effects of SGLT2i and GLP1 analogues on glucose homeostasis and cardiac enzymes in diabetic cardiomyopathy.
| Normal Control Group | Diabetes Mellitus (DM) Group | DM +SGLT2i Group | DM + GLP1 Group | |
|---|---|---|---|---|
| Blood glucose (mg/dL) | 91.50 ± 9.48 | 3698.83 ± 18.67 * | 152.33 ± 9.627 *# | 193.50 ± 9.39 *#$ |
| Insulin (U/mL) | 11.27 ± 0.29 | 6.78 ± 0.33 * | 8.60 ± 0.70 *# | 8.44 ± 0.68 *# |
| Homeostasis model assessment (HOMA) index | 2.53 ± 0.16 | 6.14 ± 0.19 * | 3.22 ± 0.31 *# | 3.97 ± 0.28 *#$ |
| LDH | 250.33 ± 22.37 | 990.00 ± 56.21 * | 292.67± 65.35 # | 296.33 ± 26.97 *# |
| CK-MB | 20.67 ± 3.44 | 271.33 ± 16.73 * | 80.17 ± 22.47 *# | 161.00 ± 58.26 *# |
All data are expressed as Mean ± SD. One-way ANOVA with Tukey Post hoc test. * Significant vs. normal control group, # significant vs. DM group, and $ significant vs. DM + SGLT2i group.